Stonnington Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Stonnington Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,100	Closed	-$383K	–	231
2022 Q2	$383K	Buy	+5,100	New	+$227K	0.1%	164
2022 Q1	–	Sell	-5,100	Closed	-$216K	–	276
2021 Q4	$216K	Buy	+5,100	New	+$228K	0.05%	230
2021 Q3	–	Sell	-3,100	Closed	-$222K	–	299
2021 Q2	$222K	Hold	3,100	–	–	0.05%	254
2021 Q1	$204K	Buy	+3,100	New	+$369K	0.05%	245

Stonnington Group's TPTX Position: Q3 2022 in Review

Stonnington Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 5,100 shares — an estimated $383K sold.

Stonnington Group first reported a position in TPTX in Q1 2021 and held it in 4 quarters. The position peaked at $383K in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Stonnington Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Stonnington Group sold 5,100 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $383K.
Stonnington Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Stonnington Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $383K in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Stonnington Group's 13F filing for Q3 2022, filed 20 Oct 2022.